Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Earnings Results, Misses Expectations By $0.01 EPS

Key Points

• Aurinia Pharmaceuticals reported an earnings per share (EPS) of $0.16, missing analysts' expectations of $0.17 by $0.01.
• The company achieved revenues of $70.01 million for the quarter, exceeding analyst estimates of $64.27 million.
• Several institutional investors have increased their stakes, including AQR Capital Management, which boosted its position by 8.7% in the first quarter.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP issued its earnings results on Thursday. The biotechnology company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01), Zacks reports. The company had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 19.57%. Aurinia Pharmaceuticals updated its FY 2025 guidance to EPS.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $10.49 on Friday. The firm has a 50 day moving average of $8.35 and a 200-day moving average of $8.13. The stock has a market capitalization of $1.42 billion, a PE ratio of 24.40 and a beta of 1.23. Aurinia Pharmaceuticals has a 12 month low of $5.20 and a 12 month high of $10.67. The company has a current ratio of 5.93, a quick ratio of 5.26 and a debt-to-equity ratio of 0.16.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Institutional investors have recently modified their holdings of the company. AQR Capital Management LLC boosted its position in Aurinia Pharmaceuticals by 8.7% during the first quarter. AQR Capital Management LLC now owns 503,543 shares of the biotechnology company's stock worth $4,048,000 after purchasing an additional 40,380 shares during the period. Royal Bank of Canada raised its stake in shares of Aurinia Pharmaceuticals by 65.3% during the first quarter. Royal Bank of Canada now owns 367,661 shares of the biotechnology company's stock worth $2,956,000 after acquiring an additional 145,179 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Aurinia Pharmaceuticals by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company's stock worth $642,000 after acquiring an additional 3,497 shares in the last quarter. 36.83% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on AUPH shares. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday. Royal Bank Of Canada upped their price objective on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a research report on Friday.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.